Daniel A Vallera

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. pmc Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
    B J Stish
    Department of Therapeutic Radiology Radiation Oncology, Section on Molecular Cancer Therapeutics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Br J Cancer 101:1114-23. 2009
  2. pmc Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model
    D A Vallera
    University of Minnesota Cancer Center, Department of Therapeutic Radiology Radiation Oncology, Minneapolis, MN 55455, USA
    Gut 57:634-41. 2008
  3. ncbi request reprint Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude mice
    D A Vallera
    University of Minnesota Cancer Center, Department of Therapeutic Radiology Radiation Oncology, Minneapolis 55455, USA
    Cancer Biother Radiopharm 18:133-45. 2003
  4. ncbi request reprint Radiotherapy of CD45-expressing Daudi tumors in nude mice with yttrium-90-labeled, PEGylated anti-CD45 antibody
    Daniel A Vallera
    Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Cancer Biother Radiopharm 22:488-500. 2007
  5. ncbi request reprint Retroviral immunotoxin gene therapy of leukemia in mice using leukemia-specific T cells transduced with an interleukin-3/Bax fusion protein gene
    Daniel A Vallera
    University of Minnesota Cancer Center, Department of Therapeutic Radiology, Section on Experimental Cancer Immunology, Minneapolis, MN 55455, USA
    Hum Gene Ther 14:1787-98. 2003
  6. pmc Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy
    Daniel A Vallera
    University of Minnesota Cancer Center, Section on Molecular Cancer Therapeutics, Department of Therapeutic Radiology Radiation Oncology, Minneapolis, MN 55455, USA
    Leuk Res 33:1233-42. 2009
  7. ncbi request reprint Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice
    Daniel A Vallera
    Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Section on Molecular Cancer Therapeutics, MMC 367, Minneapolis, MN 55455, USA
    Leuk Res 29:331-41. 2005
  8. pmc Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases
    Daniel A Vallera
    Masonic Cancer Center, Section on Molecular Cancer Therapeutics, Department of Therapeutic Radiology Radiation Oncology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Mol Cancer Ther 9:1872-83. 2010
  9. ncbi request reprint A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma
    Daniel A Vallera
    Department of Therapeutic Radiology Radiation Oncology, Section on Molecular Cancer Therapeutics, University of Minnesota Cancer Center, Minneapolis, Minnesota, USA
    Clin Cancer Res 11:3879-88. 2005
  10. ncbi request reprint Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody
    Daniel A Vallera
    Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, 55455, USA
    Clin Cancer Res 11:7920-8. 2005

Collaborators

Detail Information

Publications51

  1. pmc Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
    B J Stish
    Department of Therapeutic Radiology Radiation Oncology, Section on Molecular Cancer Therapeutics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Br J Cancer 101:1114-23. 2009
    ..Potency, immunogenicity, and toxicity are three problems that limit the use of targeted toxins in solid tumour therapy...
  2. pmc Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model
    D A Vallera
    University of Minnesota Cancer Center, Department of Therapeutic Radiology Radiation Oncology, Minneapolis, MN 55455, USA
    Gut 57:634-41. 2008
    ....
  3. ncbi request reprint Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude mice
    D A Vallera
    University of Minnesota Cancer Center, Department of Therapeutic Radiology Radiation Oncology, Minneapolis 55455, USA
    Cancer Biother Radiopharm 18:133-45. 2003
    ....
  4. ncbi request reprint Radiotherapy of CD45-expressing Daudi tumors in nude mice with yttrium-90-labeled, PEGylated anti-CD45 antibody
    Daniel A Vallera
    Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Cancer Biother Radiopharm 22:488-500. 2007
    ..Also, the final outcome may be impacted by the size of the PEG molecule used for the modification of the blood half-life...
  5. ncbi request reprint Retroviral immunotoxin gene therapy of leukemia in mice using leukemia-specific T cells transduced with an interleukin-3/Bax fusion protein gene
    Daniel A Vallera
    University of Minnesota Cancer Center, Department of Therapeutic Radiology, Section on Experimental Cancer Immunology, Minneapolis, MN 55455, USA
    Hum Gene Ther 14:1787-98. 2003
    ..Furthermore, the Bax construct may be particularly useful as a nonimmunogenic substitute for bacterial toxins in retIT...
  6. pmc Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy
    Daniel A Vallera
    University of Minnesota Cancer Center, Section on Molecular Cancer Therapeutics, Department of Therapeutic Radiology Radiation Oncology, Minneapolis, MN 55455, USA
    Leuk Res 33:1233-42. 2009
    ..DT2219ARL represents a new class of bispecific biological that can be continually improved by genetic mutation...
  7. ncbi request reprint Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice
    Daniel A Vallera
    Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Section on Molecular Cancer Therapeutics, MMC 367, Minneapolis, MN 55455, USA
    Leuk Res 29:331-41. 2005
    ..Bic3 warrants investigation as a new drug for treating T-cell malignancy and other T-cell related disorders...
  8. pmc Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases
    Daniel A Vallera
    Masonic Cancer Center, Section on Molecular Cancer Therapeutics, Department of Therapeutic Radiology Radiation Oncology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Mol Cancer Ther 9:1872-83. 2010
    ..Because 2219KDEL7mut immunogenicity was significantly reduced and the drug was highly effective in vivo, we can now give multiple drug treatments with targeted toxins in future clinical trials...
  9. ncbi request reprint A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma
    Daniel A Vallera
    Department of Therapeutic Radiology Radiation Oncology, Section on Molecular Cancer Therapeutics, University of Minnesota Cancer Center, Minneapolis, Minnesota, USA
    Clin Cancer Res 11:3879-88. 2005
    ..DT2219 has broader reactivity in recognizing B-cell malignancies, has more killing power, and requires less toxin than using individual immunotoxin, which warrants further investigation as a new drug for treating B leukemia/lymphoma...
  10. ncbi request reprint Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody
    Daniel A Vallera
    Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, 55455, USA
    Clin Cancer Res 11:7920-8. 2005
    ..These findings indicate that anti-CD22 radioimmunotherapy with Y22 is highly effective in vivo against CD22-expressing malignancies and may be a useful therapy for drug-refractory B cell leukemia patients...
  11. ncbi request reprint A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model
    Deborah A Todhunter
    Department of Neurosurgery, University of Minnesota Cancer Center, Minneapolis 55455, USA
    Protein Eng Des Sel 17:157-64. 2004
    ..These findings indicate that bispecific IT may allow treatment of a broader subset of antigenically diverse patients while simultaneously reducing the exposure to toxin required than if two separate agents were employed...
  12. ncbi request reprint Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice
    Edward Rustamzadeh
    Department of Neurosurgery, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Int J Cancer 120:411-9. 2007
    ..These results suggest that the DTAT recombinant fusion protein is highly effective in an intracranial model and DTAT might be an effective treatment for glioblastoma...
  13. ncbi request reprint Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme
    Walter A Hall
    Department of Neurosurgery, University of Minnesota Medical School, Minneapolis, Minnesota, USA
    Neurosurg Focus 20:E23. 2006
    ..Another protein, DTAT13, was synthesized to target uPAR on the neovasculature and the uPAR and interleukin-13 receptor-expressing GBM cells. The authors describe the in vitro and in vivo efficacy of DTAT and DTAT13 against GBM...
  14. pmc A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature
    Alexander K Tsai
    Department of Therapeutic Radiology Radiation Oncology, Section on Molecular Cancer Therapeutics, University of Minnesota Masonic Cancer Center, MMC 367, Minneapolis, MN 55455, USA
    J Neurooncol 103:255-66. 2011
    ..Thus, EGFATFKDEL 7mut is an effective drug for glioblastoma therapy in this murine model and warrants further study...
  15. doi request reprint Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery
    Seunguk Oh
    Section on Molecular Cancer Therapeutics, Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Masonic Cancer Center, MMC 367, Minneapolis, MN 55455, USA
    J Neurooncol 95:331-42. 2009
    ..Thus, DTEGF13 is safe and efficacious as an alternative drug for glioblastoma therapy and warrants further study...
  16. ncbi request reprint Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice
    Chunbin Li
    Department of Therapeutic Radiology Radiation Oncology, Section on Experimental Cancer Immunology, University of Minnesota Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Protein Eng 15:419-27. 2002
    ..Together, these data suggest that DT(390)IL13 may provide an important, alternative therapy for brain cancer...
  17. ncbi request reprint Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice
    Edward Rustamzadeh
    Department of Neurosurgery, University of Minnesota Cancer Research Center, Minneapolis, MN 55455, USA
    Int J Cancer 118:2594-601. 2006
    ..These results suggest that DTIL13 is as effective in an intracranial rodent model as it was in a flank model in previous studies and that DTIL13 might be an effective treatment for glioblastoma multiforme...
  18. ncbi request reprint A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer
    Brad J Stish
    Department of Therapeutic Radiology Radiation Oncology, Section on Molecular Cancer Therapeutics, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
    Clin Cancer Res 13:6486-93. 2007
    ....
  19. ncbi request reprint Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13
    Edward Rustamzadeh
    Department of Neurosurgery, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    J Neurooncol 77:257-66. 2006
    ..These studies show that DTAT13 has properties encompassing those of both DTIL13 and DTAT and warrants further consideration for clinical development...
  20. ncbi request reprint Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody
    Daniel A Vallera
    Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, MN, USA
    Cancer Biother Radiopharm 19:11-23. 2004
    ..Because radiolabeled anti-CD19 antibody can be used to deliver radiation selectively to lymphohematopoietic tissue, these data support the use of 90Y anti-CD19 antibodies in treating B-cell malignancies...
  21. pmc A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma
    Seunguk Oh
    Masonic Cancer Center, Section on Molecular Cancer Therapeutics, Department of Therapeutic Radiology Radiation Oncology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Clin Cancer Res 15:6137-47. 2009
    ..Our purpose was to reduce toxin immunogenicity using mutagenesis, measure the ability of mutated drug to elicit B-cell antitoxin antibody responses, and show that mutated drug was effective against systemic breast cancer in vivo...
  22. ncbi request reprint Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model
    Brad J Stish
    Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    J Neurooncol 87:51-61. 2008
    ..These studies show that a new co-targeting agent that simultaneously recognizes EGFR and IL-13R is more effective than its monospecific counterparts and that DTEGF13 has therapeutic advantages for glioblastoma...
  23. pmc A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model
    Seunguk Oh
    Department of Therapeutic Radiology, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Pancreas 41:789-96. 2012
    ..The objective was to test a bispecific ligand-directed toxin (BLT), with reduced immunogenicity for enhanced efficacy in targeting orthotopic pancreatic cancer in vivo...
  24. pmc Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia
    Qing Zhou
    Masonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 116:2484-93. 2010
    ..PD-1/PD-L1 blockade coupled with Treg depletion represents an important new approach that can be readily translated into the clinic to improve the therapeutic efficacy of adoptive AML-reactive CTLs in advanced AML disease...
  25. doi request reprint Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain
    Seunguk Oh
    Department of Therapeutic Radiology Radiation Oncology, Section on Molecular Cancer Therapeutics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Neurosurg 114:1662-71. 2011
    ....
  26. ncbi request reprint Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT
    Daniel A Vallera
    Section on Molecular Cancer Therapeutics, Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis 55455, USA
    J Natl Cancer Inst 94:597-606. 2002
    ....
  27. doi request reprint Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression
    Amy P N Skubitz
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
    Gynecol Oncol 130:579-87. 2013
    ..The hypothesis driving this study is that despite their low numbers in ovarian cancer tumors, CSC can be eradicated using CD133 targeted therapy and tumor growth can be inhibited...
  28. pmc Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer
    Nate N Waldron
    Department of Pharmacology, Masonic Cancer Center, University of Minnesota, MMC 367, Minneapolis, MN 55455, USA
    Mol Cancer Ther 10:1829-38. 2011
    ..This agent shows significant promise for potential development as a clinically useful therapy...
  29. ncbi request reprint Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv
    Brad J Stish
    Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
    Clin Cancer Res 13:3058-67. 2007
    ..The goal of this study was to determine if genetically adding an sFv targeting epithelial cell adhesion molecule (EpCAM) to an anti-Her2 sFv immunotoxin would result in enhanced antitumor activity...
  30. pmc A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer
    Seunguk Oh
    Therapeutic Radiology and daggerSurgery, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Pancreas 39:913-22. 2010
    ....
  31. ncbi request reprint Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme
    Edward Rustamzadeh
    Department of Neurosurgery, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    J Neurooncol 65:63-75. 2003
    ..In this article, we review our progress to date with DTAT...
  32. ncbi request reprint Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor--immunotoxin target gene
    Ni Jin
    Section on Experimental Cancer Immunology, Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Hum Gene Ther 13:497-508. 2002
    ..Together, these data indicate that gene therapy of T cells with retrovirus containing a VEGF-immunotoxin target gene may be a valid means of inhibiting a broad range of solid tumors dependent on angiogenesis...
  33. ncbi request reprint Lack of GVHD across classical, single minor histocompatibiliTy (miH) locus barriers in mice
    B R Blazar
    Department of Pediatrics, Division of Bone Marrow Transplantation, University of Minnesota Hospital and Clinic, Minneapolis 55455, USA
    Transplantation 61:619-24. 1996
    ..These results suggest a rapid downregulation or disappearance of miH antigen-reactive CTL after BMT. These data have implications for the use of in vitro assays to predict GVHD risk in recipients of miH loci-disparate donor grafts...
  34. pmc Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production
    Michelle K Gleason
    Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA
    Mol Cancer Ther 11:2674-84. 2012
    ....
  35. pmc Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia
    Qing Zhou
    Department of Pediatrics, Division of Blood and Marrow Transplantation, Masonic Cancer Center, University of Minnesota, Twin Cities, Minneapolis, MN 55455, USA
    Blood 114:3793-802. 2009
    ....
  36. pmc Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition
    Andres Wiernik
    Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Clin Cancer Res 19:3844-55. 2013
    ..We determined whether a novel bispecific killer cell engager (BiKE) signaling through CD16 and targeting CD33 could activate NK cells at high potency against acute myelogenous leukemia (AML) targets...
  37. ncbi request reprint Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors
    Jill T Schappa
    Veterinary Clinical Sciences, University of Minnesota, Minneapolis, MN, USA
    Int J Cancer 133:1936-44. 2013
    ..Our results also support the use of companion animals with cancer for further translational development of these cytotoxic molecules...
  38. pmc Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma
    Nate N Waldron
    University of Minnesota, Department of Pharmacology, Minneapolis, MN 55455, USA
    Oral Oncol 48:1202-7. 2012
    ..To investigate the efficacy of the bispecific targeted toxin, dEGFATFKDEL, on head and neck carcinoma cell lines in vitro and in vivo...
  39. ncbi request reprint A critical role for CD48 antigen in regulating alloengraftment and lymphohematopoietic recovery after bone marrow transplantation
    B R Blazar
    University of Minnesota Cancer Center and the Department of Pediatrics, Division of Bone Marrow Transplantation, University of Minnesota Hospital, Minneapolis, MN, USA
    Blood 92:4453-63. 1998
    ..Taken together, these data provide evidence that the CD48 antigen plays a critical role in regulating hematopoiesis in post-BMT...
  40. pmc CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses
    B R Blazar
    Department of Pediatrics, Division of Bone Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
    J Clin Invest 102:473-82. 1998
    ..T cells had intact responses to antigens not present during tolerization. Tolerance was long lived and not readily reversible in vivo. These data have significant implications for the use of tolerization approaches to prevent human GVHD...
  41. ncbi request reprint Recent advances in graft-versus-host disease (GVHD) prevention
    B R Blazar
    Department of Pediatrics, University of Minnesota Hospital and Clinics, Minneapolis 55455, USA
    Immunol Rev 157:79-109. 1997
    ..Collectively, these approaches are illustratrative of the progress made in extending our GVHD prevention armamentarium...
  42. pmc The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamide
    A Panoskaltsis-Mortari
    Department of Pediatrics, BMT Division, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Clin Invest 100:1015-27. 1997
    ..This demonstration of early injury after BMT indicates the need for very early therapeutic intervention before lung damage becomes profound and irreversible...
  43. ncbi request reprint Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen
    B R Blazar
    Department of Pediatrics, University of Minnesota Hospital, Minneapolis 55455, USA
    J Immunol 159:5821-33. 1997
    ..These data have implications for designing therapeutic approaches directed toward TCR targeting in humans...
  44. ncbi request reprint Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice
    A Panoskaltsis-Mortari
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Bone Marrow Transplantation, Minneapolis, USA
    Blood 92:3960-7. 1998
    ..These studies demonstrate that KGF administration, completed before conditioning, has potential as an anti-GVHD therapeutic agent...
  45. ncbi request reprint Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene
    D A Vallera
    University of Minnesota Cancer Center, Department of Therapeutic Radiology, Minneapolis 55455, USA
    Cancer Res 60:976-84. 2000
    ....
  46. ncbi request reprint Molecular modification of a recombinant anti-CD3epsilon-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model
    D A Vallera
    Departments of Therapeutic Radiology, Section on Experimental Cancer Immunology and Pediatrics, Division of Bone Marrow Transplantation University of Minnesota Cancer Center, Minneapolis, USA
    Blood 96:1157-65. 2000
    ....
  47. ncbi request reprint Immunotoxin therapy for CNS tumor
    Edward Rustamzadeh
    Department of Neurosurgery, Graduate School, University of Minnesota, Minneapolis, MN, USA
    J Neurooncol 64:101-16. 2003
    ..In this review article the history, design, toxicity, and pharmokinetics of immunotoxins will be discussed in detail...
  48. pmc Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic
    Qing Li
    Department of Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Am Chem Soc 132:17247-57. 2010
    ..Further the CSAN construct may be adapted for the preparation of other multivalent scFvs...
  49. ncbi request reprint Peptide toxins directed at the matrix dissolution systems of cancer cells
    Arthur E Frankel
    Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Protein Pept Lett 9:1-14. 2002
    ..These recombinant fusion proteins provide a novel class of anti-cancer agents that will enter clinical trials in the next several years...
  50. ncbi request reprint Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein
    Arthur E Frankel
    Department of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Exp Hematol 30:1316-23. 2002
    ..The work also suggests that blast proliferation assays yield similar responses to leukemia colony-forming cell colony assays...
  51. ncbi request reprint The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells
    Jason G Ramage
    Department of Cancer Biology, Wake Forest University School of Medicine, Medical Center Boulevard, 27157, Winston Salem, NC, USA
    Leuk Res 27:79-84. 2003
    ....